Shanghai, China - December 18, 2025 - MicroPort CardioFlow Medtech Corporation (“MicroPort CardioFlow”) today announced that its flagship transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty®, along with its retrievable delivery system, has received market approval in Morocco. This milestone marks the product’s first entry into the African market.
Morocco’s medical device sector depends largely on imports, and in recent years, its regulatory environment has increasingly aligned with European standards. As a result, product approvals in Morocco are considered significant reference points within the region. The approval of VitaFlow Liberty® establishes a strong regulatory and clinical foundation for MicroPort CardioFlow’s further expansion across Africa.
Accelerating Global Momentum
The year 2025 marked a period of exponential international growth for VitaFlow Liberty®, with the product now commercially available across Europe, the Americas, Asia, and Africa. In November, the company reached a key milestone by surpassing 1,000 overseas commercial implants.
Highlights include:
To date, MicroPort CardioFlow’s TAVI products have entered 35 countries and regions, reaching more than 800 leading hospitals and benefiting over 17,000 patients living with aortic valve disease.
Looking Ahead
MicroPort CardioFlow will continue to advance its globalization strategy, further supported by its recently announced strategic merger with MicroPort CRM. The combined capabilities of both companies aim to establish a comprehensive platform in structural heart, cardiac rhythm management (CRM), and heart failure, accelerating access to life-changing technologies worldwide.
About MicroPort CardioFlow
MicroPort CardioFlow is an innovation leader in the global structural heart disease interventional treatment field. It holds a leading position in the Chinese transcatheter aortic valve implantation (TAVI) market and has officially entered a new phase of scaled global operations and high-quality development. Through independent R&D and collaborative development with global partners, MicroPort CardioFlow has built a forward-looking innovative pipeline covering transcatheter solutions for aortic, mitral, and tricuspid valve diseases, interventional treatment for post-myocardial infarction ventricular septal defects, and stroke prevention related to atrial fibrillation, continuously leading industry technological innovation and global market expansion.
More information is available at: https://en.cardioflowmedtech.com/